SCHEMBL22917045

SCHEMBL22917045

CC(C)NC(=O)C1CN(C(=O)NC(C)C)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.46
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44
CHRNA4 P43681 1/20 0.44
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 2/20 0.41
GAA P10253 1/20 0.41
CYP1A2 P05177 3/20 0.41
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP2D6 P10635 2/20 0.39
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14355655 0.84 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2APKMTSHR
SCHEMBL22916977 0.84 MEN1 (0.50) SMN1; SMN2MEN1KMT2ATSHRCHRNB2
SCHEMBL22916938 0.82 MEN1 (0.49) SMN1; SMN2MEN1KMT2ATSHRCHRNB2
SCHEMBL24568203 0.82 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2APKMTSHR
SCHEMBL22916960 0.79 MEN1 (0.46) SMN1; SMN2MEN1KMT2ATSHRCHRNB2
SCHEMBL18390288 0.79 MEN1 (0.49) SMN1; SMN2MEN1KMT2ATSHRCHRNB2
SCHEMBL12448072 0.79 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2APKMTSHR
SCHEMBL15298999 0.79 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2APKMTSHR
SCHEMBL4089082 0.78 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2APKMTSHR
SCHEMBL20353633 0.78 TSHR (0.47) SMN1; SMN2MEN1KMT2ATSHRCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 SMN1; SMN2 376/4885MEN1 41/4885KMT2A 2349/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 SMN1; SMN2 376/4885MEN1 41/4885KMT2A 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.